These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8580818

  • 1. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
    Eberlé F, Toiron Y, Camerlo J, Lafage M, Sainty D, Arnoulet C, Raineri V, Gabert J, Maraninchi D, Mannoni P.
    Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
    [Abstract] [Full Text] [Related]

  • 2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 3. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 4. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R.
    J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
    [Abstract] [Full Text] [Related]

  • 5. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T, Gaiger A, Henn T, Hörth E, Haas OA, Geissler K, Gadner H.
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [Abstract] [Full Text] [Related]

  • 6. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R, Estrov Z, Kantarjian H, Talpaz M.
    J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
    [Abstract] [Full Text] [Related]

  • 7. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
    Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N.
    Blood; 1991 Nov 01; 78(9):2188-93. PubMed ID: 1932740
    [Abstract] [Full Text] [Related]

  • 8. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G, Testoni N, Amabile M, Bonifazi F, De Vivo A, Farabegoli P, Terragna C, Montefusco V, Ottaviani E, Saglio G, Russo D, Baccarani M, Rosti G, Tura S.
    Bone Marrow Transplant; 2000 Apr 01; 25(7):729-36. PubMed ID: 10745258
    [Abstract] [Full Text] [Related]

  • 9. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
    Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NC.
    Leukemia; 1997 Apr 01; 11 Suppl 3():541-4. PubMed ID: 9209451
    [Abstract] [Full Text] [Related]

  • 10. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.
    Blood; 2000 Jan 01; 95(1):62-6. PubMed ID: 10607685
    [Abstract] [Full Text] [Related]

  • 11. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
    Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.
    Blood; 1996 Feb 15; 87(4):1549-55. PubMed ID: 8608246
    [Abstract] [Full Text] [Related]

  • 12. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS, Chielens D, Raskind W, Bryant E, Flowers ME, Radich J, Clift R, Appelbaum F.
    Blood; 1997 Oct 01; 90(7):2549-54. PubMed ID: 9326220
    [Abstract] [Full Text] [Related]

  • 13. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
    Reiter A, Marley SB, Hochhaus A, Sohal J, Raanani P, Hehlmann R, Gordon MY, Goldman JM, Cross NC.
    Br J Haematol; 1998 Sep 01; 102(5):1271-8. PubMed ID: 9753056
    [Abstract] [Full Text] [Related]

  • 14. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ, Li W, Kong LH, Wang GJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb 01; 11(1):38-40. PubMed ID: 12667287
    [Abstract] [Full Text] [Related]

  • 15. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
    Jiang Q, Zhao XY, Qin YZ, Liu YR, Lai YY, Jiang B, Huang XJ.
    Am J Hematol; 2012 Dec 01; 87(12):1065-9. PubMed ID: 22965919
    [Abstract] [Full Text] [Related]

  • 16. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
    Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M.
    Leukemia; 1992 Aug 01; 6(8):754-60. PubMed ID: 1640725
    [Abstract] [Full Text] [Related]

  • 17. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G, Roy DC, Gonin R, Alyea EP, Bélanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C.
    J Clin Oncol; 1995 Jul 01; 13(7):1704-13. PubMed ID: 7602361
    [Abstract] [Full Text] [Related]

  • 18. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
    Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.
    Br J Haematol; 1995 Sep 01; 91(1):126-31. PubMed ID: 7577619
    [Abstract] [Full Text] [Related]

  • 19. Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing interferon alpha therapy: follow-up with reverse polymerase chain reaction.
    Bilhou-Nabera C, Viard F, Marit G, Gharbi MJ, Salzes S, Reiffers J, Broustet A, Bernard P.
    Leukemia; 1992 Jun 01; 6(6):595-8. PubMed ID: 1602797
    [Abstract] [Full Text] [Related]

  • 20. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
    Chomel JC, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, Guilhot F, Brizard A.
    Blood; 2000 Jan 15; 95(2):404-8. PubMed ID: 10627442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.